Loading cancer entity…
Loading cancer entity…
Clinical trials
53 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06440005 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Angiex, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06898970 | Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma | recruiting | Phase 2 | 18 | Varun Monga, MBBSOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05859074 |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer |
| recruiting |
| Phase 1 |
| 56 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Aug 12, 2026 |
| clinicaltrials |
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer(I-SPY) | recruiting | Phase 2 | 5,000 | QuantumLeap Healthcare CollaborativeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07432932 | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients(PANTHR-S) | recruiting | — | 800 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06715579 | Cardiac Angiosarcoma International Registry(CAIR) | recruiting | — | 500 | Immune Oncology Research InstituteOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04055220 | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas(REGOSTA) | recruiting | N/A | 168 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06375941 | Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars(ProStars) | recruiting | — | 250 | Italian Sarcoma GroupNETWORK | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT05961761 | Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients(PROPANE) | recruiting | Phase 2 | 80 | Niels JunkerOTHER | 3 | Jul 27, 2023 | clinicaltrials |
Data updated 21 days agoSource updated Sep 9, 2026source: clinicaltrials